Experimental drug aims to shrink head and neck cancers before surgery
NCT ID NCT05312710
First seen Jan 17, 2026 · Last updated May 16, 2026 · Updated 19 times
Summary
This study tests an oral drug called APG-157 in 24 people with newly diagnosed head and neck cancer. The goal is to see if taking the drug before standard treatments like surgery can shrink tumors and improve outcomes. Researchers will measure tumor size changes using scans and check immune markers in biopsies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
VAGLAHS, West Los Angeles
Los Angeles, California, 90073, United States
Conditions
Explore the condition pages connected to this study.